Funding for this research was provided by:
Umea University
Article History
Accepted: 24 August 2023
First Online: 13 September 2023
Declarations
: Johan Lilja declares no conflicts of interest.
: Anders Själander was the principal investigator of the RE-VERSE AD study in Sweden and has received consultancy or lecture fees from Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Merck Sharp and Dohme, Portola and Pfizer.
: Sara Själander has received consultancy or lecture fees from Bayer, Bristol Myers Squibb and Pfizer.